Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Prologis Inc (PLD) Price & Performance

Gilead Sciences, Inc.Trade
Prologis IncTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Prologis Inc — how do they compare? Gilead Sciences, Inc. trades at $135.19 (market cap $168.35B), while Prologis Inc trades at $139.28 (market cap $132.57B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Prologis Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals.

GILDPLD
Market Cap
$168.35B$132.57B
Sector
HealthReal Estate
52-Week High
$155.80$149.96
52-Week Low
$110.56$104.81
Enterprise Value
$191.42B$167.31B
Dividend Yield
2.42%3.07%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Prologis Inc

Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.

Read more on PLD